| Optimizing the start time of statin therapy for patients with diabetes BT Denton, M Kurt, ND Shah, SC Bryant, SA Smith Medical Decision Making 29 (3), 351-367, 2009 | 109 | 2009 |
| Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence JE Mason, DA England, BT Denton, SA Smith, M Kurt, ND Shah Medical Decision Making 32 (1), 154-166, 2012 | 59 | 2012 |
| Optimally maintaining a Markovian deteriorating system with limited imperfect repairs M Kurt, JP Kharoufeh European Journal of Operational Research 205 (2), 368-380, 2010 | 59 | 2010 |
| The structure of optimal statin initiation policies for patients with type 2 diabetes M Kurt, BT Denton, AJ Schaefer, ND Shah, SA Smith IIE Transactions on Healthcare Systems Engineering 1 (1), 49-65, 2011 | 53 | 2011 |
| Monotone optimal replacement policies for a Markovian deteriorating system in a controllable environment M Kurt, JP Kharoufeh Operations Research Letters 38 (4), 273-279, 2010 | 53 | 2010 |
| From data to improved decisions: operations research in healthcare delivery M Capan, A Khojandi, BT Denton, KD Williams, T Ayer, J Chhatwal, ... Medical Decision Making 37 (8), 849-859, 2017 | 33 | 2017 |
| Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients ND Shah, J Mason, M Kurt, BT Denton, AJ Schaefer, VM Montori, ... PloS one 6 (1), e16170, 2011 | 22 | 2011 |
| Structured replacement policies for a Markov-modulated shock model M Kurt, LM Maillart Operations Research Letters 37 (4), 280-284, 2009 | 13 | 2009 |
| What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell … SL Klijn, E Fenwick, S Kroep, K Johannesen, B Malcolm, M Kurt, C Kiff, ... PharmacoEconomics 39 (3), 345-356, 2021 | 6 | 2021 |
| Dynamic decision models for managing the major complications of diabetes M Kurt University of Pittsburgh, 2012 | 6 | 2012 |
| Valuing prearranged paired kidney exchanges: A stochastic game approach M Kurt, MS Roberts, AJ Schaefer, MU Unver Boston College Working Papers in Economics, 2011 | 6 | 2011 |
| PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS S Kroep, C Kiff, C Kraan, M Bianco, K Johannesen, M Kurt, B Malcolm, ... Value in Health 22, S523-S524, 2019 | 3 | 2019 |
| Optimizing over Pure Stationary Equilibria in Consensus Stopping Games A Dehghanian, M Kurt, AJ Schaefer forthcoming at Mathematical Programming Computation, 2018 | 3 | 2018 |
| Comparative effectiveness of up to three lines of chemotherapy treatment plans for metastatic colorectal cancer I Toumazis, M Kurt, A Toumazi, LG Karacosta, C Kwon MDM policy & practice 2 (2), 2381468317729650, 2017 | 3 | 2017 |
| Chance-constrained programming models and approximations for general stochastic bottleneck spanning tree problems S Shen, M Kurt, J Wang INFORMS Journal on Computing 27 (2), 301-316, 2015 | 3 | 2015 |
| At what lipid ratios should a patient with type 2 diabetes initiate statins M Kurt, B Denton, AJ Schaefer, N Shah, S Smith IIE Transactions on Healthcare Engineering 1 (1), 49-65, 2009 | 3 | 2009 |
| Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial JS Weber, ... ESMO 2019, 2019 | 2 | 2019 |
| Lipid Ratio-Based Statin Initiation for Patients with Type 2 Diabetes M Kurt, BT Denton, AJ Schaefer, ND Shah, S Smith | 1 | 2008 |
| Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma V Federico Paly, M Kurt, L Zhang, MO Butler, O Michielin, A Amadi, ... MDM policy & practice 7 (1), 23814683221089659, 2022 | | 2022 |
| Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection. BA McGregor, S Petersohn, S Klijn, J May, F Ejzykowicz, M Kurt, M Dyer, ... Journal of Clinical Oncology 40 (6_suppl), 391-391, 2022 | | 2022 |
